INTRODUCTION
============

Depression is a common mental disorder and one of the leading causes of morbidity and disability worldwide.[@b1-cpn-14-026],[@b2-cpn-14-026] Additionally, depression is associated with significant economic burdens due to missed work and/or reduced productivity at work.[@b3-cpn-14-026] Difficulties in attention/concentration are integrated in the diagnostic criteria of major depressive disorder (MDD).[@b4-cpn-14-026] Residual cognitive dysfunction has been associated with the non-remission or increased probability of relapse of a depressive episode[@b5-cpn-14-026] and impaired levels of functioning and work ability.[@b6-cpn-14-026] Thus, the improvement of cognitive function is an important aim for the treatment of depression[@b7-cpn-14-026] and the accurate evaluation of cognitive deficits is the first step towards this goal.

Cognitive symptoms can be assessed using objective neuropsychological tests performed by clinicians or based on the subjective reports of patients. A wide variety of neuropsychological tests have been validated and used in depression research[@b8-cpn-14-026] but many of these tests are limited when used in clinical settings because they are too time-intensive for a busy real world practice, an expert is required to administer the test, and their associations with other functional outcomes have yet to be determined.[@b9-cpn-14-026] The use of subjective cognitive measures can mitigate the limitations associated with objective neuropsychological measures because the subjective tests assess the cognitive symptoms related to the individual perceptions and experiences of patients in their daily lives.

To date, no measures have been specifically designed for the evaluation of subjective cognitive symptoms in depressive patients. The Perceived Deficits Questionnaire (PDQ), which is a subjective cognitive measure, was originally developed for use in patients with multiple sclerosis.[@b10-cpn-14-026] The PDQ scores of patients with multiple sclerosis are correlated with scores on depression scales but not with neuropsychological test scores,[@b11-cpn-14-026] which suggests that the PDQ may be used to evaluate cognitive difficulties related to depression. Hence, the PDQ has been adapted to depressive patients recently. The adapted version included minor modification compared to the original one and is called PDQ-Depression (PDQ-D). PDQ-D has begun to be validated in depressive patients.[@b12-cpn-14-026]--[@b14-cpn-14-026]

The primary goal of the present study was to standardize a formal Korean version of the PDQ-D (K-PDQ-D). For this purpose, the internal consistency, reliability, factorial analyses, concurrent validity, and predictive validity of the K-PDQ-D were examined.

METHODS
=======

Study Participants
------------------

The present study recruited 128 MDD patients from two university hospitals (Chonnam National University Hospital and Asan Medical Center) in South Korea from October 2013 to December 2014. The inclusion criteria for participation in this study were as follows: i) a current or new diagnosis of a major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition, text revision (DSM-IV-TR) and confirmed with the Mini-International Neuropsychiatric Interview (MINI),[@b15-cpn-14-026] ii) status as an outpatient of either sex aged 19--65 years, and iii) starting an antidepressant monotherapy either as newly initiated or switched from a previous monotherapy. The exclusion criteria were as follows: i) a diagnosis of schizophrenia or other psychotic disorder, bipolar disorder, substance dependence, dementia or other neurodegenerative disease that could significantly impact cognitive functioning, or a mood disorder due to a general medical condition or substance use, ii) pregnant or breastfeeding women, or women who were 6 months post-partum, iii) the inability to read or understand the information sheet, informed consent form, or patient-report questionnaires, iv) concurrent participation in a clinical trial, and/or v) acute suicidality based on the judgment of a clinician. A total of 128 patients were evaluated at study entry and after a 12-week regimen of anti-depressant monotherapy, and the remaining 86 patients completed a follow-up assessment. The present study was approved by the institutional review boards of Chonnam National University Hospital and Asan Medical Center and all participants provided written informed consent.

Perceived Deficits Questionnaire
--------------------------------

The PDQ-D consists of 20 items that construct four domains of cognitive function: attention/concentration (Items 1, 5, 9, 13, and 17), retrospective memory (Items 2, 6, 10, 14, and 18), prospective memory (Items 3, 7, 11, 15, and 19), and organization/planning (Items 4, 8, 12, 16, and 20). The PDQ-D was translated into Korean with minor relevant modifications that reflected the unique Korean culture and situation; the K-PDQ-D is available in the [online supplement material](#s1-cpn-14-026){ref-type="supplementary-material"} of the present study. The administration and scoring methods for the K-PDQ-D are the same as the original PDQ. Briefly, the respondents rate the frequency of each complaint on a 5-point Likert scale anchored from never (0) to almost always (4) in a self-report form; each domain is scored out of 20 and higher scores indicate more severe cognitive dysfunction. The present study used the total score and the four domain scores for the analyses.

Demographic Characteristics
---------------------------

The demographic characteristics of the patients were evaluated at study entry by a clinical research coordinator using a structured case report form (CRF). Data were obtained regarding age, gender, duration of formal education, and current occupation (current employed status or not).

Clinical Characteristics and Assessment Scales
----------------------------------------------

The MDD diagnoses were made by the treating clinicians using DSM-IV-TR criteria and the guidance of MINI. At study entry, the clinical research coordinators assessed all other clinical characteristics, including a history of previous depressive episodes (recurrent or first episode), using the structured CRF. Information regarding concurrent chronic medical disorders was gathered using a questionnaire that inquired about six disorders, and these data were recoded as the presence or absence of any medical disorder for the present analyses. Depression severity was measured with the Montgomery-Asberg Depression Rating Scale (MADRS), which consists of 10 items that provide a total score ranging from 0--60.[@b16-cpn-14-026] Disability was assessed using the Sheehan Disability Scale (SDS), which consists of three items that provide a total score ranging from 0--30.[@b17-cpn-14-026] Quality of life was measured using the EuroQol-5 dimensions questionnaire (EQ-5D) health status thermometer, which ranges from 0--100.[@b18-cpn-14-026] Sick leave days (missed school or work) in the previous week due to the depressive symptoms were also estimated. Higher scores on the MADRS and SDS, lower scores on the EQ-5D, and a greater number of sick leave days were considered to indicate a more severe symptomatology or impact of MDD. These assessment scales were evaluated at study entry and the 12-week endpoint of the study.

Treatment-related Characteristics
---------------------------------

The choice of an antidepressant for each patient was determined by the independent decision of their respective clinicians. The antidepressant types were divided into three categories: i) selective serotonin reuptake inhibitors including citalopram, escitalopram, fluoxetine, paroxetine, and sertraline, ii) newer antidepressants such as bupropion, venlafaxine, and mirtazapine, and iii) older anti-depressants such as amitriptyline, clomipramine, imipramine, milnacipran, nortriptyline, tianeptine, and trazodone. The use of concomitant medications such as anxiolytics and/or hypnotics was allowable if the medication was not another type of antidepressant or an antipsychotic. All adverse events reported by the patients during the study period were recorded by the clinical research coordinators.

Statistical Analyses
--------------------

The descriptive data obtained at the study entry and 12-week evaluations are presented as means±standard deviations or as percentages, where appropriate. The scores at study entry for the patients that did and did not complete the follow-up evaluation were compared using *t*-tests or Mann-Whitney *U*-tests, respectively. The reliability analyses of the K-PDQ-D were conducted by evaluating internal consistency using Cronbach's alpha coefficient, estimating split-half reliability using Guttman's split-half coefficient, and determining test-retest reliability between the scores at study entry and follow-up scores using intra-class correlation coefficients (ICCs). For the factor analyses, a principal component analysis with varimax rotation and Kaiser normalization was used to extract the main factors, which had eigenvalues \>1.0. The concurrent validities of the K-PDQ-D scores at study entry with the other assessment scales and the predictive validities of the K-PDQ-D scores at study entry with the changed scores on the other assessment scales (follow-up scores minus scores at study entry) were examined using Spearman's rho correlation tests. All statistical analyses were performed using the PASW Statistics ver. 18.0 software (IBM Co., Armonk, NY, USA).

RESULTS
=======

Patient Sample and Characteristics
----------------------------------

A total of 128 MDD patients were enrolled at study entry, and 86 (67%) patients followed up at 12-week end point. The demographic, clinical, and treatment-related characteristics of the 128 at study entry and 86 follow-up patients are described in the first and second columns of [Table 1](#t1-cpn-14-026){ref-type="table"}, respectively. Compared to the patients who did not complete the follow-up assessment, the follow-up patients were significantly older, less educated, and had more chronic medical disorders. The scores on the assessment scales, including the K-PDQ-D, did not significantly differ between these two groups (all *p*\>0.05). The scores on the assessment scales measured at follow-up are described in the third column of [Table 1](#t1-cpn-14-026){ref-type="table"}; in general, the assessment scale scores improved after 12 weeks of anti-depressant monotherapy treatment (all *p*\<0.01).

Reliability Analyses
--------------------

The reliability analyses of the K-PDQ-D are summarized in [Table 2](#t2-cpn-14-026){ref-type="table"}. In the sample at study entry, the Cronbach's alpha and Guttman's split-half coefficients were high for the total scores as well as for each of the four domain scores on the K-PDQ-D. In the follow-up sample, the ICCs between the study entry and follow-up scores on the K-PDQ-D were high for the total scores and for all four domains. Overall, the K-PDQ-D exhibited good results in all reliability analyses.

Factor Structure of the PDQ-K
-----------------------------

The factorial analyses of the K-PDQ-D in the sample at study entry are summarized in [Table 3](#t3-cpn-14-026){ref-type="table"}. Four factors with eigenvalues \>1.0 were extracted and together they explained 62.8% of the variance. The four-factor structure of the K-PDQ-D was similar to the original PDQ and 16 of the 20 K-PDQ-D items (80%) exactly matched the factor structure of the original PDQ (bold type in [Table 3](#t3-cpn-14-026){ref-type="table"}).

Concurrent Validity
-------------------

The concurrent validities of the K-PDQ-D scores at study entry with the other assessment scales in the sample at study entry are summarized in [Table 4](#t4-cpn-14-026){ref-type="table"}. The higher total scores and domain scores on the K-PDQ-D were significantly correlated with higher scores on the MADRS, the number of sick leave days, and the lower scores on the EQ-5D health status. The higher total scores and attention/concentration and organization/planning domain scores were significantly correlated with higher SDS scores. Overall, these data suggest that subjectively worse cognitive function was cross-sectionally associated with a decrease in all symptoms and functions related to depression.

Predictive Validity
-------------------

The predictive validities of the K-PDQ-D scores at study entry with the changed scores on the other assessment scales from the study entry to follow-up are summarized in [Table 5](#t5-cpn-14-026){ref-type="table"}. The higher attention/concentration domain scores on the K-PDQ-D were significantly correlated with increase in the number of sick leave days, and the higher retrospective memory domain scores were significantly correlated with an increase in the number of sick leave days and lower EQ-5D health status scores. Additionally, higher prospective memory was significantly correlated with lower EQ-5D health status stores.

DISCUSSION
==========

The principal findings of the present instrument standardization study using Korean MDD patients were that the newly developed K-PDQ-D showed good internal consistency and split-half and test-retest reliabilities and that it had a similar factor structure to the original PDQ version with high coefficients of determination. Furthermore, the K-PDQ-D reflected various symptoms and functions that were cross-sectionally related to depression and predicted the number of sick leave days taken from work and the health-related quality of life after 12 weeks of anti-depressant treatment.

Despite the high prevalence and negative impact of cognitive dysfunction, the validities of subjective instruments for the evaluation of the cognitive function of depressive patients have only recently begun to be investigated.[@b12-cpn-14-026]--[@b14-cpn-14-026] The present study is one of in this area and it demonstrated significant findings. The coefficients on the Cronbach's alpha and Guttman's split-half analyses were high for the total scores and all four domain scores, which indicates that the questionnaire construction of the K-PDQ-D was consistent across the 20 items. The test-retest reliability at study entry and after 12 weeks of treatment was also good, which suggests that the K-PDQ-D reflected particular individual characteristics, even after treatment.

A study of multiple sclerosis patients found the original PDQ to be composed of four factors[@b10-cpn-14-026] and a recent study of whiplash disorder patients also extracted four factors.[@b19-cpn-14-026] The two PDQ studies that focused on depressive patients did not conduct factorial analyses[@b12-cpn-14-026],[@b13-cpn-14-026] and, therefore, the present study was the first to investigate the factor structure of the PDQ using depressive patients. Interestingly, despite the use of different study populations, the same four main factors were extracted from the K-PDQ-D in the present study as in the original version of the PDQ.[@b10-cpn-14-026] Furthermore, there was a substantial overlap (80%) in the item composition of each factor. These findings suggest that the PDQ can be used to assess patients with depression as well as those with physical disorders and that PDQ scores can be compared in similar contexts among different disease groups.

The K-PDQ-D scores were significantly correlated with the MADRS and SDS scores as well as the number of sick leave days and EQ-5D health status. These are encouraging findings which indicate that subjective cognitive dysfunction as measured by the K-PDQ-D reflected not only depressive symptoms per se but also disability, absenteeism, and quality of life, which are multi-dimensional aspects of depression. The prospective data of the present study demonstrated that some of the domain scores on the K-PDQ-D significantly predicted sick leave days taken from work and health-related quality of life but not the severity of depression or disability after 12 weeks of antidepressant monotherapy. Objective assessments of cognitive performance have been shown to significantly predict later impaired work ability in depressive patients[@b6-cpn-14-026] but the present findings regarding subjective cognitive dysfunction are novel in this field of research. These findings suggest that the K-PDQ-D may have unique or different psychometric properties relative to other assessment scales of depression and, therefore, it would be a rational to administer the K-PDQ-D during depression research and clinical practice to predict work productivity and quality of life. However, as with other novel findings, these results should be reexamined using a larger depression cohort as well as using other patient populations with physical disorders.

The strengths of the present study include the use of a structured research protocol, well-recognized and standardized scales, and a prospective study design, which is rare in instrument standardization studies. The limitations of the present study include the fact that the sociodemographic data, clinical characteristics, and burden of MDD were unknown for the excluded patient populations due to the particular study inclusion and exclusion criteria. The particular treatment modalities for each patient were determined by the respective treating clinicians rather than by any formal guidelines and, therefore, inter-clinician variability may have affected the observed outcomes. The sample size was not sufficient for the new scale development, particularly for the factorial analyses. Additionally, the sample was drawn from two university hospitals, and therefore did not represent the Korean depressive patients as a whole. However, the demographic and clinical characteristics of the patients in the present study were comparable to those in a representative Korean clinical study of depression that included over 700 patients (mean age: 47.9 years, 74.4% female, and 34.2% with chronic medical disorders).[@b20-cpn-14-026]

In conclusion, the present study demonstrated that the K-PDQ-D was a reliable and valid instrument for the assessment of depressive patients. Recently, cognitive symptoms have begun to be considered as one of the primary outcomes of depression treatment[@b21-cpn-14-026] and the efficacies of several antidepressants for the improvement of cognitive function in MDD patients have been investigated.[@b22-cpn-14-026],[@b23-cpn-14-026] The K-PDQ-D, which is a brief questionnaire for the evaluation of subjective cognitive symptoms in depressive patients, could offer a standard and efficient approach to facilitate the identification of cognitive symptoms and aid the progression toward treatment goals. It is strongly recommended that this instrument be administered as a complementary tool to the existing assessment scales for the gathering of unique information that may be critical for the comprehensive evaluation of depressive patients.
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###### 

Sample characteristics

  Characteristic                        Sample at study entry (n=128)   Followed-up sample (n=86)                              
  ------------------------------------- ------------------------------- ------------------------------------------------------ -----------
  Demographic characteristic                                                                                                   
   Age (yr)                             47.0±11.5                       48.8±11.1[\*](#tfn2-cpn-14-026){ref-type="table-fn"}   NA
   Gender (women)                       93 (72.7)                       60 (69.8)                                              NA
   Education (yr)                       11.7±4.0                        10.9±4.2[†](#tfn3-cpn-14-026){ref-type="table-fn"}     NA
   Occupation (have)                    49 (38.3)                       32 (37.2)                                              NA
  Clinical characteristic                                                                                                      
   Recurrent depression                 32 (25.0)                       20 (23.3)                                              NA
   Chronic medical disorder             61 (47.7)                       50 (58.1)[†](#tfn3-cpn-14-026){ref-type="table-fn"}    NA
   MADRS (score)                        28.0±7.1                        28.6±7.2                                               10.0±8.7
   SDS (score)                          20.0±7.9                        20.3±8.0                                               9.4±8.6
   Sick leave (days in the last week)   2.5±2.8                         2.6±2.9                                                2.0±2.5
   EQ-5D health status (score)          49.7±20.1                       50.2±18.4                                              66.2±21.9
    PDQ-K (score)                                                                                                              
     Total                              24.4±16.0                       23.3±15.5                                              15.2±15.4
     Attention/concentration            7.3±4.7                         6.9±4.6                                                4.0±4.5
     Retrospective memory               4.6±4.2                         4.5±4.1                                                3.2±4.0
     Prospective memory                 5.2±4.0                         4.9±3.9                                                3.9±3.9
     Organization/planning              7.4±5.2                         7.1±5.1                                                4.1±4.6
  Treatment related characteristic                                                                                             
   Administered antidepressants type                                                                                           
    SSRIs                               77 (60.2)                       48 (55.8)                                              NA
    Newer antidepressants               48 (37.5)                       36 (41.9)                                              NA
    Older antidepressants               3 (2.3)                         2 (2.3)                                                NA
   Concomitant anxiolytics/hypnotics    71 (55.5)                       51 (59.3)                                              NA
   Reported drug side effects           18 (14.0)                       13 (15.1)                                              NA

Values are presented as mean±standard devation or number (%).

*p*\<0.05,

*p*\<0.01 in comparisons between those lost and follow-up by *t*-tests, χ^2^ tests, or Mann-Whitney *U*-tests, as appropriate.

MADRS, Montgomery Asberg Depression Rating Scale; SDS, Sheehan Disability Scale; EQ-5D, EuroQol-5 dimensions questionnaire; K-PDQ-D, Korean version of Perceived Deficits Questionnaire-Depression; SSRIs, selective serotonin reuptake inhibitors; NA, not available.

###### 

Results of reliability analyses of the Korean version of Perceived Deficits Questionnaire-Depression (K-PDQ-D)

  K-PDQ-D                   Sample at study entry (n=128)   Followed-up sample (n=86)   
  ------------------------- ------------------------------- --------------------------- -------
  Total                     0.928                           0.947                       0.598
  Attention/concentration   0.751                           0.725                       0.501
  Retrospective memory      0.827                           0.805                       0.622
  Prospective memory        0.750                           0.720                       0.671
  Organization/planning     0.847                           0.836                       0.438

###### 

Factor structure of the Korean version of Perceived Deficits Questionnaire-Depression (K-PDQ-D) at study entry (n=128)

  PDQ-K item number   Factor 1    Factor 2    Factor 3    Factor 4
  ------------------- ----------- ----------- ----------- -----------
  1                                                       **0.411**
  2                                           **0.712**   
  3                                           0.801       
  4                               **0.776**               
  5                                                       0.724
  6                                           0.633       
  7                   **0.611**                           
  8                               **0.735**               
  9                               0.652                   
  10                                          **0.583**   
  11                  **0.444**                           
  12                              **0.717**               
  13                                                      **0.431**
  14                  0.604                               
  15                  **0.543**                           
  16                              **0.423**               
  17                  0.756                               
  18                                          **0.410**   
  19                  **0.545**                           
  20                              **0.481**               
  \% variance         18.1        18.0        15.4        11.3
  Eigenvalue          3.6         3.6         3.1         2.3

Factor 1 is matching to Prospective memory; Factor 2 to Organization/planning; Factor 3 to Retrospective memory; Factor 4 to Attention/concentration domains of the original PDQ version. In particular, values in bold type are matching to the four factor structure of the original PDQ version.

###### 

Concurrent validity of the Korean version of Perceived Deficits Questionnaire-Depression (K-PDQ-D) with other assessment scales at study entry (n=128)

  K-PDQ-D                   MADRS                                              SDS                                                Sick leave days                                    EQ-5D health status
  ------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  Total                     +0.394[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   +0.304[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   +0.443[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   −0.313[‡](#tfn8-cpn-14-026){ref-type="table-fn"}
  Attention/concentration   +0.403[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   +0.350[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   +0.376[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   −0.310[‡](#tfn8-cpn-14-026){ref-type="table-fn"}
  Retrospective memory      +0.249[†](#tfn7-cpn-14-026){ref-type="table-fn"}   +0.166                                             +0.330[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   −0.265[†](#tfn7-cpn-14-026){ref-type="table-fn"}
  Prospective memory        +0.293[†](#tfn7-cpn-14-026){ref-type="table-fn"}   +0.166                                             +0.425[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   −0.236[†](#tfn7-cpn-14-026){ref-type="table-fn"}
  Organization/planning     +0.395[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   +0.320[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   +0.378[‡](#tfn8-cpn-14-026){ref-type="table-fn"}   −0.270[†](#tfn7-cpn-14-026){ref-type="table-fn"}

Values are Spearman's rho coefficients.

*p*\<0.01,

*p*\<0.001.

MADRS, Montgomery Asberg Depression Rating Scale; SDS, Sheehan Disability Scale; EQ-5D, EuroQol-5 dimensions questionnaire.

###### 

Predictive validity of the Korean version of Perceived Deficits Questionnaire-Depression (K-PDQ-D) measured at study entry with changes in other assessment scales scores from the study entry to follow-up (n=86)

  K-PDQ-D                   MADRS    SDS      Sick leave days                                      EQ-5D health status
  ------------------------- -------- -------- ---------------------------------------------------- ----------------------------------------------------
  Total                     −0.014   −0.030   +0.190                                               −0.196
  Attention/concentration   −0.049   −0.083   +0.213[\*](#tfn11-cpn-14-026){ref-type="table-fn"}   −0.163
  Retrospective memory      +0.029   −0.014   +0.217[\*](#tfn11-cpn-14-026){ref-type="table-fn"}   −0.235[\*](#tfn11-cpn-14-026){ref-type="table-fn"}
  Prospective memory        +0.055   +0.037   +0.012                                               −0.277[†](#tfn12-cpn-14-026){ref-type="table-fn"}
  Organization/planning     −0.050   −0.031   +0.200                                               −0.092

Values are Spearman's rho coefficients.

*p*\<0.05,

*p*\<0.01.

MADRS, Montgomery Asberg Depression Rating Scale; SDS, Sheehan Disability Scale; EQ-5D, EuroQol-5 dimensions questionnaire.
